179 related articles for article (PubMed ID: 35649245)
1. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers MFJM; Heuberger JAAC; Groeneveld GJ; Oude Nijhuis J; De Deyn PP; Hadi S; Harris J; Tsai RM; Cruz-Herranz A; Huang F; Tong V; Erickson R; Zhu Y; Scearce-Levie K; Hsiao-Nakamoto J; Tang X; Chang M; Fox BM; Estrada AA; Pomponio RJ; Alonso-Alonso M; Zilberstein M; Atassi N; Troyer MD; Ho C
Clin Transl Sci; 2022 Aug; 15(8):2010-2023. PubMed ID: 35649245
[TBL] [Abstract][Full Text] [Related]
2. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers.
Grievink HW; Heuberger JAAC; Huang F; Chaudhary R; Birkhoff WAJ; Tonn GR; Mosesova S; Erickson R; Moerland M; Haddick PCG; Scearce-Levie K; Ho C; Groeneveld GJ
Clin Pharmacol Ther; 2020 Feb; 107(2):406-414. PubMed ID: 31437302
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
Hincelin-Mery A; Nicolas X; Cantalloube C; Pomponio R; Lewanczyk P; Benamor M; Ofengeim D; Krupka E; Hsiao-Nakamoto J; Eastenson A; Atassi N
Clin Transl Sci; 2024 Jan; 17(1):e13690. PubMed ID: 38010108
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized, double-blinded, placebo-controlled study assessing the safety and pharmacokinetics of RIPK1 inhibitor GFH312 in healthy subjects.
Lickliter J; Wang S; Zhang W; Zhu H; Wang J; Zhao C; Shen H; Wang Y
Clin Transl Sci; 2023 Sep; 16(9):1691-1703. PubMed ID: 37345561
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
[TBL] [Abstract][Full Text] [Related]
6. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants.
Sun ALA; Gillies JD; Shen Y; Deng H; Xue F; Ma Y; Song L
Clin Transl Sci; 2024 Jul; 17(7):e13857. PubMed ID: 38949195
[TBL] [Abstract][Full Text] [Related]
7. Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response.
Li W; Shan B; Zou C; Wang H; Zhang MM; Zhu H; Naito MG; Xu D; Manuel VJ; Mifflin L; Hou Z; Ravits J; Yuan J
Cell Res; 2022 Jul; 32(7):621-637. PubMed ID: 35661830
[TBL] [Abstract][Full Text] [Related]
8. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis.
Mifflin L; Hu Z; Dufort C; Hession CC; Walker AJ; Niu K; Zhu H; Liu N; Liu JS; Levin JZ; Stevens B; Yuan J; Zou C
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33766915
[TBL] [Abstract][Full Text] [Related]
9. Targeting RIPK1 for the treatment of human diseases.
Degterev A; Ofengeim D; Yuan J
Proc Natl Acad Sci U S A; 2019 May; 116(20):9714-9722. PubMed ID: 31048504
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects.
Tompson DJ; Davies C; Scott NE; Cannons EP; Kostapanos M; Gross AS; Powell M; Ino H; Shimamura R; Ogura H; Nagakubo T; Igarashi H; Nakano A
Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):71-83. PubMed ID: 33165774
[TBL] [Abstract][Full Text] [Related]
11. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target.
Mifflin L; Ofengeim D; Yuan J
Nat Rev Drug Discov; 2020 Aug; 19(8):553-571. PubMed ID: 32669658
[TBL] [Abstract][Full Text] [Related]
12. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
Li S; Qu L; Wang X; Kong L
Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965
[TBL] [Abstract][Full Text] [Related]
13. Receptor-Interacting Protein Kinase 1 (RIPK1) as a Potential Therapeutic Target: An Overview of Its Possible Role in the Pathogenesis of Alzheimer's Disease.
Chan HH; Koh RY; Lim CL; Leong CO
Curr Alzheimer Res; 2019; 16(10):907-918. PubMed ID: 31642777
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Izzo NJ; Yuede CM; LaBarbera KM; Limegrover CS; Rehak C; Yurko R; Waybright L; Look G; Rishton G; Safferstein H; Hamby ME; Williams C; Sadlek K; Edwards HM; Davis CS; Grundman M; Schneider LS; DeKosky ST; Chelsky D; Pike I; Henstridge C; Blennow K; Zetterberg H; LeVine H; Spires-Jones TL; Cirrito JR; Catalano SM
Alzheimers Dement; 2021 Aug; 17(8):1365-1382. PubMed ID: 33559354
[TBL] [Abstract][Full Text] [Related]
15. Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
Weisel K; Berger S; Papp K; Maari C; Krueger JG; Scott N; Tompson D; Wang S; Simeoni M; Bertin J; Peter Tak P
Clin Pharmacol Ther; 2020 Oct; 108(4):808-816. PubMed ID: 32301501
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
17. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS.
Ito Y; Ofengeim D; Najafov A; Das S; Saberi S; Li Y; Hitomi J; Zhu H; Chen H; Mayo L; Geng J; Amin P; DeWitt JP; Mookhtiar AK; Florez M; Ouchida AT; Fan JB; Pasparakis M; Kelliher MA; Ravits J; Yuan J
Science; 2016 Aug; 353(6299):603-8. PubMed ID: 27493188
[TBL] [Abstract][Full Text] [Related]
18. The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease.
Hugon J; Paquet C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808629
[TBL] [Abstract][Full Text] [Related]
19. RIPK1 mediates a disease-associated microglial response in Alzheimer's disease.
Ofengeim D; Mazzitelli S; Ito Y; DeWitt JP; Mifflin L; Zou C; Das S; Adiconis X; Chen H; Zhu H; Kelliher MA; Levin JZ; Yuan J
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):E8788-E8797. PubMed ID: 28904096
[TBL] [Abstract][Full Text] [Related]
20. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
